Premium
M‐ VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant
Author(s) -
Soloway Mark S.,
Ishikawa Satoru,
Taylor Tammy,
Ezell Gilbert
Publication year - 1989
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930420509
Subject(s) - medicine , cystectomy , vinblastine , cisplatin , methotrexate , transitional cell carcinoma , adjuvant , chemotherapy , vincristine , urology , oncology , doxorubicin , surgery , toxicity , induction chemotherapy , bladder cancer , cancer , cyclophosphamide
The cisplatin‐ based combination chemotherapy regimens of M‐ VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty‐ eight percent of the patients with metastatic disease had a complete (20%) or partial (28%) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M‐ VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is greater.